Mylan NV (NASDAQ:MYL) Director Melina E. Higgins acquired 20,000 shares of the business’s stock in a transaction on Thursday, August 15th. The shares were purchased at an average price of $17.68 per share, with a total value of $353,600.00. Following the completion of the purchase, the director now owns 33,120 shares in the company, valued at approximately $585,561.60. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of Mylan stock traded up $0.66 on Monday, hitting $19.19. 5,649,536 shares of the company were exchanged, compared to its average volume of 6,969,182. The stock has a market capitalization of $9.08 billion, a price-to-earnings ratio of 4.19, a price-to-earnings-growth ratio of 0.83 and a beta of 1.77. The company has a 50-day moving average price of $19.09 and a 200 day moving average price of $23.55. Mylan NV has a 1-year low of $16.63 and a 1-year high of $39.59. The company has a quick ratio of 0.77, a current ratio of 1.37 and a debt-to-equity ratio of 1.15.
Mylan (NASDAQ:MYL) last issued its earnings results on Monday, July 29th. The company reported $1.03 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.95 by $0.08. The business had revenue of $2.85 billion for the quarter, compared to analysts’ expectations of $2.82 billion. Mylan had a return on equity of 18.93% and a net margin of 0.30%. The business’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.07 EPS. Research analysts forecast that Mylan NV will post 4.3 EPS for the current year.
Several research firms have commented on MYL. BidaskClub upgraded Mylan from a “sell” rating to a “hold” rating in a research note on Thursday, June 20th. BMO Capital Markets set a $36.00 price objective on Mylan and gave the stock a “buy” rating in a research note on Wednesday, May 8th. Credit Suisse Group reiterated a “buy” rating and set a $34.50 price objective on shares of Mylan in a research note on Wednesday, July 31st. Wells Fargo & Co lowered Mylan from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $33.00 to $22.00 in a research note on Tuesday, May 7th. Finally, Cantor Fitzgerald cut their price objective on Mylan from $31.00 to $18.00 and set a “neutral” rating for the company in a research note on Wednesday, June 12th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have issued a buy rating to the company’s stock. Mylan presently has a consensus rating of “Buy” and an average price target of $30.43.
Mylan Company Profile
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.